Research Article
Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
Table 1
Efficacy of tofogliflozin on various metabolic parameters.
| | Parameters | Baseline | 4 weeks | | 12 weeks | |
| | Body weight (kg) | 89.0 ± 3.1 | 87.2 ± 3.1 | <0.01 | 85.7 ± 3.0 | <0.01 | | Body mass index (kg/m2) | 32.2 ± 0.8 | 31.5 ± 0.9 | <0.01 | 31.3 ± 0.8 | <0.01 | | HbA1c (%) | 8.3 ± 0.2 | 7.7 ± 0.1 | <0.01 | 7.3 ± 0.1 | <0.01 | | Systolic BP (mmHg) | 131.0 ± 2.6 | 126.4 ± 2.5 | n.s. | 126.8 ± 2.4 | n.s. | | Diastolic BP (mmHg) | 76.3 ± 1.9 | 76.2 ± 1.9 | n.s. | 76.3 ± 1.7 | n.s. | | Triglyceride (mg/dL) | 216.3 ± 24.7 | 214.1 ± 26.6 | n.s. | 173.2 ± 16.1 | n.s. | | LDL cholesterol (mg/dL) | 112.0 ± 4.4 | 107.1 ± 4.8 | n.s. | 107.2 ± 4.3 | n.s. | | HDL cholesterol (mg/dL) | 48.3 ± 2.6 | 42.4 ± 2.0 | n.s. | 45.5 ± 2.0 | n.s. | | Uric acid (mg/dL) | 5.6 ± 0.3 | 5.3 ± 0.2 | <0.05 | 4.9 ± 0.2 | <0.05 | | Hematocrit (%) | 45.6 ± 1.2 | 44.2 ± 1.2 | n.s. | 46.2 ± 0.7 | n.s. |
|
|
